

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method of treating a mammal suffering from uveal melanoma comprising administering to said mammal in need of such a treatment, a therapeutically effective dose of 4-(4-methyl piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]-benzamide or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The method according to claim 1 wherein the uveal melanoma is a metastasizing uveal melanoma.

Claim 3 (canceled)

Claim 4 (previously presented): The method according to claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in the form of a monosulfonate salt.

Claim 5 (previously presented): The method according to claim 4 wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in the beta crystal form.

Claim 6 (currently amended): The method according to claim 1 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered at a daily dose corresponding to 100 mg to 1000 mg of Compound I free base.

Claim 7 (previously presented): The method according to claim 6 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered once daily for a period exceeding 3 months.

Claims 8-10 (canceled)